Physiomics (PYC) Competitors

GBX 1.25
0.00 (0.00%)
(As of 05/14/2024 ET)

PYC vs. NFX, OCTP, APTA, OVB, FAB, EVG, IXI, VAL, BSFA, and ROQ

Should you be buying Physiomics stock or one of its competitors? The main competitors of Physiomics include Nuformix (NFX), Oxford Cannabinoid Technologies (OCTP), Aptamer Group (APTA), Ovoca Bio (OVB), Fusion Antibodies (FAB), Evgen Pharma (EVG), IXICO (IXI), ValiRx (VAL), BSF Enterprise (BSFA), and Roquefort Therapeutics (ROQ). These companies are all part of the "biotechnology" industry.

Physiomics vs.

Physiomics (LON:PYC) and Nuformix (LON:NFX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk, community ranking and dividends.

In the previous week, Physiomics' average media sentiment score of 0.00 equaled Nuformix'saverage media sentiment score.

Company Overall Sentiment
Physiomics Neutral
Nuformix Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Physiomics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Nuformix
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Physiomics received 12 more outperform votes than Nuformix when rated by MarketBeat users. However, 66.67% of users gave Nuformix an outperform vote while only 55.56% of users gave Physiomics an outperform vote.

CompanyUnderperformOutperform
PhysiomicsOutperform Votes
80
55.56%
Underperform Votes
64
44.44%
NuformixOutperform Votes
68
66.67%
Underperform Votes
34
33.33%

Physiomics has higher revenue and earnings than Nuformix.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Physiomics£900.71K1.70N/AN/AN/A
Nuformix£50K30.64-£1.20MN/AN/A

0.1% of Physiomics shares are held by institutional investors. Comparatively, 0.2% of Nuformix shares are held by institutional investors. 6.3% of Physiomics shares are held by insiders. Comparatively, 15.0% of Nuformix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Nuformix has a net margin of 0.00% compared to Physiomics' net margin of -70.32%. Nuformix's return on equity of -27.25% beat Physiomics' return on equity.

Company Net Margins Return on Equity Return on Assets
Physiomics-70.32% -62.94% -37.22%
Nuformix N/A -27.25%-17.20%

Physiomics has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500. Comparatively, Nuformix has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500.

Summary

Nuformix beats Physiomics on 8 of the 11 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PYC vs. The Competition

MetricPhysiomicsBiotechnology IndustryMedical SectorLON Exchange
Market Cap£1.53M£173.47M£4.99B£1.46B
Dividend Yield6.20%3.43%39.14%11.75%
P/E Ratio-13.83248.97139.021,693.71
Price / Sales1.7014,433.932,426.28300,559.69
Price / Cash4.2111.4032.7833.38
Price / BookN/A6.295.012.74
Net IncomeN/A-£15.99M£103.74M£175.91M
7 Day Performance-16.30%0.40%-0.05%1.07%
1 Month Performance-5.83%4.97%-0.37%3.11%
1 Year Performance-60.35%5.17%5.72%10.58%

Physiomics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NFX
Nuformix
0 of 5 stars
GBX 0.19
flat
N/A-30.2%£1.52M£50,000.00-1.633Gap Down
OCTP
Oxford Cannabinoid Technologies
0 of 5 stars
GBX 0.14
-60.9%
N/A-87.5%£1.49MN/A-53.107Gap Down
High Trading Volume
APTA
Aptamer Group
0 of 5 stars
GBX 0.62
-12.1%
N/A-93.8%£2.87M£1.03M-7.6937
OVB
Ovoca Bio
0 of 5 stars
GBX 0.75
flat
N/A-87.1%£612,000.00N/A-37.505Gap Up
FAB
Fusion Antibodies
0 of 5 stars
GBX 3.46
+1.8%
N/A-90.9%£3.30M£1.58M-38.4448
EVG
Evgen Pharma
0 of 5 stars
GBX 0.80
flat
N/A-79.5%£3.42MN/A-80.0010
IXI
IXICO
0 of 5 stars
GBX 7.75
-4.6%
N/A-62.2%£3.75M£6.67M-387.5089
VAL
ValiRx
0 of 5 stars
GBX 3.10
-5.9%
N/A-69.0%£4.11MN/A-103.478Gap Down
BSFA
BSF Enterprise
0 of 5 stars
GBX 5
-8.3%
N/A-66.4%£5.17MN/A-250.0012Gap Down
ROQ
Roquefort Therapeutics
0 of 5 stars
GBX 4.55
+5.8%
N/AN/A£5.88M£637.00-455.009

Related Companies and Tools

This page (LON:PYC) was last updated on 5/14/2024 by MarketBeat.com Staff

From Our Partners